References
- The Health Sector Transformation Program [Internet]. 2022. [cited 2022 Mar 1]. Available from: https://www.vision2030.gov.sa/v2030/vrps/hstp/
- Current health expenditure (% of GDP) - Saudi Arabia | Data [Internet]. The World Bank. 2023 [cited 2023 May 29]. Available from: https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=SA
- Alrasheedy AA. Pharmaceutical pricing policy in Saudi Arabia: findings and implications. GaBi J. 2020;9(1):14–21. doi: 10.5639/gabij.2020.0901.003
- Blandizzi C, Meroni PL, Lapadula G. Comparing originator biologics and biosimilars: a review of the relevant issues. Clin Ther. 2017;39(5):1026–1039. doi: 10.1016/j.clinthera.2017.03.014
- Simoens S, Cheung R. Tendering and biosimilars: what role for value-added services? J Mark Access Heal Policy. 2020;8(1):1705120. doi: 10.1080/20016689.2019.1705120
- Batran RA, Elmoshneb M, Hussein AS, et al. Biosimilars: science, implications, and potential outlooks in the Middle East and Africa. Biol Targets Ther. 2022;Volume 16:161–171. doi: 10.2147/BTT.S376959
- Chen Y, Monnard A, da Silva JS An inflection point for biosimilars [Internet]. McKinsey Co. 2022 [cited 2023 Mar 1]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/an-inflection-point-for-biosimilars
- Bassil N, Sasmaz S, El Sayah M, et al. Realizing biosimilar potential in the Middle East & Africa [Internet]. IQVIA. 2020. p. 1–28. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/mea/white-paper/biosimilar_iqvia-whitepaper_final.pdf
- AlRuthia Y, Bahari OH, Alghnam S, et al. Real-world impact of switching from insulin glargine (Lantus(®)) to Basaglar(®) and potential cost saving in a large public healthcare system in Saudi Arabia. Front Public Health. 2022;10:852721. doi: 10.3389/fpubh.2022.852721
- AlRuthia Y, Almadi M, Aljebreen A, et al. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. J Med Econ. 2020;23(10):1102–1110. doi: 10.1080/13696998.2020.1791889
- Saudi Food & Drug Authority. Guideline on Biosimilar Products [Internet]. Version 1.0. 2017 [cited 2023 Mar 1]. p. 1–17. Available from: https://www.sfda.gov.sa/sites/default/files/2021-03/Guideline-on-biosimilar-products-EN.pdf
- Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology. 2017;56(suppl_4):iv14–iv29. doi: 10.1093/rheumatology/kex278
- Webster CJ, Woollett GR. A “Global Reference”. Comparator For Biosimilar Development. BioDrugs. 2017;31:279–286. doi: 10.1007/s40259-017-0227-4
- Prior S, Metcalfe C, Hufton SE, et al. Maintaining ‘standards’ for biosimilar monoclonal antibodies. Nat Biotechnol. 2021;39(3):276–280. doi: 10.1038/s41587-021-00848-0
- van Meer PJK, Ebbers HC, Kooijman M, et al. Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Drug Discov Today. 2015;20(4):483–490. doi: 10.1016/j.drudis.2014.11.009
- Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–1028. doi: 10.1056/NEJMoa063842
- Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–634. doi: 10.1007/s40259-019-00377-y
- Frapaise F-X. The end of phase 3 clinical trials in biosimilars development? BioDrugs. 2018;32:319–324. doi: 10.1007/s40259-018-0287-0
- Bielsky M-C, Cook A, Wallington A, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020;25(11):1910–1918. doi: 10.1016/j.drudis.2020.09.006
- Schiestl M, Ranganna G, Watson K, et al. The path towards a tailored clinical biosimilar development. BioDrugs. 2020;34:297–306. doi: 10.1007/s40259-020-00422-1
- Druedahl LC, Kälvemark Sporrong S, Minssen T, et al. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution. PLoS One. 2022;17(1):e0262537. doi: 10.1371/journal.pone.0262537
- Aljahili S, Alshuwairikh S, Alkhaldi A, et al. Safety of interchanging from reference biologic to its biosimilar: A systematic review and meta-analysis [Internet]. ISPOR. 2022 [cited 2023 May 29]. Available from: https://www.ispor.org/heor-resources/presentations-database/presentation/euro2022-3566/118233
- Saudi Food & Drug Authority. Guidance for Naming of Medicinal Products [Internet]. Version 2.1. 2020 [cited 2023 Mar 1]. p. 1–19. Available from: https://beta.sfda.gov.sa/sites/default/files/2021-04/GuidanceforNamingofMedicinalProductsV2.1_0.pdf
- Saudi Food & Drug Authority. Pricing Rules for Pharmaceutical Products [Internet]. 2021 [cited 2023 Mar 1]. p. 1–22. Available from: https://www.sfda.gov.sa/sites/default/files/2022-10/PharmaceuticalPricingRulesE.pdf
- Saudi Food & Drug Authority. Guideline on good pharmacovigilance practices (GVP) [Internet]. Version 3.1. 2023 [cited 2023 Mar 1]. p. 1–368. Available from: https://sfda.gov.sa/sites/default/files/2023-01/Drug-GVP_0.pdf
- Wilsdon T, Pistollato M, Ross-Stewart K, et al. Biosimilars: A global roadmap for policy sustainability. Charles River Associates. 2022.
- Omair MA, Alhawassi T, Alwaihibi M, et al. Improving the understanding of originator and biosimilar biologics among healthcare providers in Saudi Arabia. Saudi Pharm J. 2020;28:1827–1829. doi: 10.1016/j.jsps.2020.11.008
- Böhm A-K, Steiner IM, Stargardt T. Market diffusion of biosimilars in off-patent biologic drug markets across Europe. Health Policy (New York. Health Policy. 2023;132:104818. InternetAvailable from: https://www.sciencedirect.com/science/article/pii/S0168851023001033
- Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi: 10.1016/j.semarthrit.2021.11.009
- Khan MA, Aseeri MA, Alshamrani MA, et al. Emerging role of biosimilars in oncology-hematology in Saudi Arabia: a practical perspective. Glob J Qual Saf Healthc. 2020;3(1):22–29. doi: 10.4103/JQSH.JQSH_15_19
- Yousef CC, Khan MA, Almodaimegh H, et al. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: Simulation study. Journal Of Medical Economics. 2023;26(1):394–402. doi: 10.1080/13696998.2023.2183680
- Omair MA, Almadany R, Omair MA, et al. Perception of biosimilar biologics and non-medical prescription switching among rheumatologists: a Saudi society for rheumatology initiative. Saudi Pharm J. 2022;30:39–44. doi: 10.1016/j.jsps.2021.10.012
- Barbier L, Ebbers HC, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734–755. doi: 10.1002/cpt.1836
- Ismail S, Abu Esba L, Khan M, et al. An institutional guide for formulary decisions of biosimilars. Hosp Pharm. 2023;58(1):38–48. doi: 10.1177/00185787221138007
- Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford). 2017;56(suppl_4):iv30–iv48. InternetAvailable from. doi: 10.1093/rheumatology/kex277
- Mysler E, Azevedo VF, Danese S, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021;81(16):1859–1879. doi: 10.1007/s40265-021-01610-1
- Bhardwaja B, Klocke S, Ekinci E, et al. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System. BioDrugs. 2021;36(1):1–11. doi: 10.1007/s40259-021-00510-w
- Yoo DH, Choe J-Y, Shim SC, et al. Switching to biosimilars in the treatment of rheumatic diseases. Expert Rev Clin Immunol [InternetAvailable from]. 2018;14:557–571. doi: 10.1080/1744666x.2018.1490178
- Allocati E, Godman B, Gobbi M, et al. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022;13:1–20. doi: 10.3389/fphar.2022.917814
- Somaily M, Alahmari H, Abbag W, et al. Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching. Generics Biosimilars Initiat J. 2021;10(2):68–71. InternetAvailable from: http://gabi-journal.net/biosimilars-in-saudi-arabia-a-single-centre-open-label-case-series-examining-infliximab-switching.html
- Islami MM, Khan MA, Aseeri MA, et al. Comparison of biosimilar filgrastim with innovator fligrastim for peripheral blood stem cells mobilization, collection of CD34+ stem cells, and engraftment in patients undergoing autologous and allogeneic stem cell transplantation: A single-center experie. Ann Transplant [Internet]. 2023; In press. https://annalsoftransplantation.com/abstract/index/idArt/938585
- Fontanillo M, Körs B, Monnard A. Short peptide pharmacophores developed from protein phosphatase-1 disrupting peptides (PDPs). Bioorg Med Chem. 2022;65: doi: 10.1016/j.bmc.2022.116785
- Williams T. An evaluation of the biologics price competition and innovation act and its impact on innovation in the pharmaceutical industry. Rochester Institute of Technology; 2022.